The shares of the Pharma company, specializing in developing and distributing pharmaceuticals for respiratory, dermatology, and oncology conditions, jumped upto 4 percent upon declaring Q4 results and announcing a 250 percent Dividend.
With a market capitalization of Rs. 39,554.68 crores on Monday, the shares of Glenmark Pharmaceuticals Ltd jumped upto 4.02 percent in Intraday trade, making a high of Rs. 1430.50 per share compared to its open price of Rs. 1375.15 per share.
Glenmark Pharmaceuticals Ltd, engaged in the research, development, manufacturing, and marketing of pharmaceutical products, including both generic and branded formulations, as well as Active Pharmaceutical Ingredients (APIs), has announced its Q4 results and Dividend as follows.
Its Revenue from operations rose by 6 percent YoY from Rs. 3,063 Crores in Q4FY24 to Rs. 3,256 Crores in Q4FY25, and it declined by 4 percent QoQ from Rs. 3,388 Crores in Q3FY25 to Rs. 3,256 Crores in Q4FY25. Its Net Profit YoY went from a loss of Rs. 1,214 Crores in Q4FY24 to a profit of Rs. 4.38 Crores in Q4FY25, and it declined by 98 percent QoQ from a profit of Rs. 348 Crores in Q3FY25 to Rs. 4.38 Crores in Q4FY25.
The earnings per share (EPS) for the quarter stood at Rs. 0.16, compared to Rs. 12.33 in the previous quarter. The company maintains a low debt-to-equity ratio of 0.28, indicating strong financial stability. It delivers a healthy ROE of 14.89 percent and a solid ROCE of 16.77 percent.
Along with it, the company has recommended a dividend of 250 percent (Rs. 2.50 per share, face value of Rs. 1 each) for the financial year 2024-25, subject to approval by shareholders at the upcoming Annual General Meeting.
Also read: Pharma stock jumps over 4% after signing global supply deal; Plans ₹650–750 Cr capex
Key Highlights in FY25 & Others
In FY25, Glenmark achieved a leadership position in key therapeutic areas, ranking 2nd in Dermatology, 2nd in Respiratory, and 3rd in Cardiac in India. The company successfully launched RYALTRIS in over 10 markets, now commercialized in 45+ markets globally. Glenmark’s Europe business grew by 17.6 percent in FY25.
In terms of Regional distribution in Q4FY25, India contributes 29 percent, North America accounts for 21.9 percent, Europe makes up 22.5 percent, Rest of the World (ROW) contributes 24.3 percent, and Other Revenue stands at 2.3 percent.
Written By Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
